Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP study of MRKAd5 HIV-1 gag/pol/nef vaccine
NCT00095576Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2004
- Primary completion
- Sep 2007
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
Phase 2, randomised, double-blind trial of trivalent MRKAd5 HIV-1 gag/pol/nef vaccine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Number of Participants With Clinical Adverse Experiences, Number of Participants With Laboratory Adverse Experiences and 2 more. Started Nov 2004; status: terminated.
02
Drugs
trivalent MRKAd5 HIV-1 gag/pol/nef vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00095576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095576.